Troluce Capital Advisors LLC Roivant Sciences Ltd. Transaction History
Troluce Capital Advisors LLC
- $826 Million
- Q2 2024
A detailed history of Troluce Capital Advisors LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Troluce Capital Advisors LLC holds 2,950,000 shares of ROIV stock, worth $36.5 Million. This represents 3.78% of its overall portfolio holdings.
Number of Shares
2,950,000Holding current value
$36.5 Million% of portfolio
3.78%Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
308Shares Held
496MCall Options Held
989KPut Options Held
1.15M-
Sb Investment Advisers (Uk) LTD London, X071.4MShares$883 Million6.97% of portfolio
-
Viking Global Investors LP69.2MShares$856 Million2.91% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$826 Million72.99% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$438 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.3MShares$363 Million0.02% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.72B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...